The effects of psilocybin and MDMA on between-network resting-state functional connectivity
Also known as: Roseman et al. 2014 psilocybin MDMA connectivity, Psilocybin between-network connectivity, The effects of psilocybin and MDMA on between-network resting state functional connectivity
This dossier is a research synthesis sourced using AI, not documentary evidence. Use the reference leads to check important claims.
This dossier concerns a 2014 Imperial College London pharmacological functional-MRI comparison generally recalled as Roseman and colleagues’ study, “The effects of psilocybin and MDMA on between-network resting state functional connectivity.” It is best understood as a small, early resting-state neuroimaging study of altered-state brain correlates in healthy volunteers, rather than as evidence for psi, extrasensory perception, telepathy, or any other paranormal capacity. Its central analytical question was whether acute administration of psilocybin, a serotonergic classic psychedelic, and MDMA, an empathogen-entactogen with substantial monoaminergic actions, changed functional relationships between canonical large-scale brain networks. The comparison was scientifically useful because the substances can both alter affect, salience, self-experience, and social or emotional processing, while differing in pharmacology, typical subjective profile, duration, and cultural framing. A contrast between them can potentially identify patterns more associated with the psychedelic state than with nonspecific drug intoxication, scanner arousal, positive mood, expectancy, or general autonomic activation. The title’s focus on “between-network” connectivity is important. Resting-state functional connectivity usually means a statistical association, commonly temporal correlation, between low-frequency blood-oxygen-level-dependent signal fluctuations in regions or networks during a scan without an externally imposed cognitive task. It does not directly measure neurons communicating, information transmission, causal influence, synaptic connectivity, or conscious content. In this line of work, canonical systems of interest commonly include the default-mode network, task-positive or frontoparietal attention-related systems, salience-related systems, and sensory networks. Healthy waking brains often show partly segregated network organization: some systems exhibit stronger internally coherent coupling, while pairs of systems can show weak or negative associations under particular preprocessing choices. The reported conceptual result of the paper is that psilocybin was associated with greater communication, or reduced segregation, between normally more distinct networks. This was treated as compatible with a broader model in which psychedelic experience relaxes usual constraints on brain-network organization. The study belongs to the formative period of modern psychedelic neuroimaging at Imperial College London, associated with Robin L. Carhart-Harris, David Nutt, Amanda Feilding, and collaborators. It should be situated alongside earlier Imperial findings on psilocybin and default-mode-network activity or integrity, as well as later formulations such as the entropic brain hypothesis and REBUS/relaxed-beliefs models. However, this paper should not be collapsed into those related publications. It addressed a specific connectivity level—relations among networks—and apparently used data that may overlap partly or wholly with other early Imperial psilocybin datasets. Therefore, apparent agreement across papers from this research program is not necessarily independent replication. The MDMA arm likewise needs careful verification: the exact dosing route, timing, placebo/control procedure, whether the same participants received both agents, whether cohorts were separate, and the usable fMRI sample after exclusions are all material to interpretation. The reported comparison is often summarized too simply as “psilocybin makes the brain more connected.” That shorthand is inadequate. Connectivity can increase for some pairs while decrease for others; within-network integrity and between-network coupling can move in different directions; and a result depends on seed definitions, independent-component or network decomposition method, nuisance regression choices, temporal filtering, treatment of global signal, and motion censoring. A reduction in apparent anti-correlation, for example, may be described as increased coupling, but its magnitude and even interpretive framing can be affected by global-signal regression. Likewise, acute psychoactive drugs can alter respiration, heart rate, vascular tone, alertness, head movement, and susceptibility-related signal quality. These changes can enter BOLD correlations without demonstrating a drug effect on neural network integration alone. The study’s conclusions are thus most defensible as condition-associated changes in a particular fMRI connectivity analysis, subject to methodological qualifications. Psilocybin and MDMA offer a potentially revealing but imperfect comparison. Psilocybin is primarily associated with agonism at serotonin 5-HT2A receptors, although its system-level effects are not reducible to one receptor. MDMA has prominent serotonin-releasing effects and also affects dopamine and norepinephrine systems, with physiological and affective consequences. Subjectively, psilocybin may produce visual alterations, altered time sense, unusual ideation, changes in self-boundaries, and at higher intensity ego-dissolution-like experiences. MDMA is more commonly associated with stimulation, positive affect, emotional openness, sociability, and empathy, though individual responses vary substantially. If the paper found a more marked psilocybin-related reduction of network segregation than MDMA, that pattern would support—but not prove—the interpretation that cross-network reorganization is more characteristic of the psychedelic phenomenology than of pleasant mood or stimulation alone. Conversely, any shared effect could reflect a common monoaminergic, affective, physiological, or expectancy-related component rather than a common psychological construct. The setting also matters. Resting-state scans occur in a constrained, noisy, supine environment, typically with participants asked to remain still and rest with eyes closed or open according to the protocol. Such a setting is not equivalent to naturalistic psychedelic use, psychotherapy, a social MDMA setting, or long-term clinical change. A scan captures a limited acute time window, often selected around expected drug effects. It cannot establish whether observed connectivity differences cause subjective experiences, whether they are consequences of those experiences, or whether they predict durable therapeutic outcomes. The sample in this generation of studies was generally modest and not representative of clinical populations, people with psychiatric comorbidity, or broad demographic populations. Screening and medical supervision also make the findings inapplicable to unsupervised use without further evidence. Transmission history has favored broad, memorable narratives: the “default mode network is turned off,” the “brain becomes globally integrated,” or psychedelics “rewire the brain.” These formulations draw loosely on real network-science findings but exceed what a single cross-sectional or within-subject resting-state contrast can show. The original article was published in a period of renewed public and commercial interest in psychedelic medicine. Later clinical-development, wellness, media, and investment narratives have given especially high visibility to mechanistic claims about brain flexibility and connectivity. A neutral cross-case system should distinguish the paper’s measured variables from its later popular interpretation, and should distinguish acute pharmacological effects from claims of therapeutic efficacy. It should also avoid treating the MDMA comparator as a placebo or as a pure control for emotional warmth, because it has its own strong neural, cardiovascular, and behavioral effects. For comparative research, the durable motifs are: acute drug challenge; resting-state BOLD fMRI; canonical-network segregation versus integration; a psychedelic versus non-classic psychoactive comparator; subjective-state correlation; small specialist research cohorts; analytic sensitivity to preprocessing; overlapping datasets across multiple publications; and later rhetorical expansion from statistical coupling to claims about consciousness. The 2024 psilocybin network-integrity work associated with Siegel and collaborators is relevant as a later, thematically related follow-up, but it is not the same underlying study and should not be merged. A rigorous verification pass should locate the final article, inspect its methods and supplementary materials, identify its exact data provenance, compare all drug and placebo conditions, establish correction for multiple comparisons, and determine whether reported subjective correlations were primary analyses or exploratory analyses.
- Words
- 2,443
- Observations
- 12
- Reference leads
- 4
- Validation score
- 100/100
Chronology
The work appears to arise from the early-2010s revival of controlled psychedelic neuroimaging at Imperial College London, where psilocybin resting-state studies were already examining default-mode and other large-scale systems.
In 2014, Roseman and collaborators reportedly published the specific between-network resting-state functional-connectivity comparison involving psilocybin and MDMA. The exact online-publication and issue dates should be checked in the journal record.
Subsequent papers from Imperial and other groups developed related claims about reduced network integrity, reduced segregation, altered modularity, and increased cross-network coupling under psychedelics. These later studies should not automatically be counted as independent confirmations because some early papers reused overlapping samples or analytic datasets.
During the 2020s, larger or denser-sampling psilocybin imaging studies renewed interest in network segregation and integrity, while also making sample size, replication, preprocessing, and generalizability more explicit methodological issues.
People, organisations, and setting
The recalled author group includes Leor Roseman as lead author and collaborators linked to Imperial College London’s psychedelic research program, including Robin L. Carhart-Harris, David J. Nutt, Amanda Feilding, and Robert Leech. Exact author order and all affiliations require verification against the publication.
Imperial College London in the United Kingdom was the institutional setting recalled for the research. The work was conducted in a medically supervised research context, not in a clinical treatment program or informal recreational setting.
Participants were reportedly healthy volunteers. Their number, sex distribution, prior substance experience, psychiatric screening criteria, recruitment procedures, compensation, and whether psilocybin and MDMA data came from identical or partly distinct participant groups should be treated as unverified until methods are checked.
The scanner environment likely imposed stillness, acoustic noise, restricted movement, and a brief resting instruction. These situational features can shape both subjective drug experience and data quality.
Reported measures and phenomena
The primary reported phenomenon was altered resting-state BOLD functional connectivity between established brain networks during acute drug effects. It was a statistical imaging observation, not a direct observation of neural messages crossing networks.
The recalled psilocybin pattern involved increased between-network functional connectivity or reduced separation between ordinarily distinct networks. The precise network pairs, direction of each contrast, and correction threshold require direct checking.
The paper’s framing is consistent with a possible co-occurrence between diminished network segregation and characteristic psychedelic changes in self-processing or cognition. Such a relationship is correlational and does not demonstrate that a connectivity change produces ego dissolution or any other experience.
MDMA was used as an active psychoactive comparison rather than a neutral baseline. Its effects on mood, arousal, autonomic state, movement, and attention make it informative but not a clean control for every nonspecific factor.
Design and analytic investigation
The study reportedly used resting-state fMRI to compare drug conditions with placebo or baseline conditions. Verification should establish whether the design was crossover, randomized, double-blind, placebo-controlled, or composed of separate experiments.
Functional connectivity analyses may have used predefined network maps, seed-based correlations, independent-component approaches, or combinations of these methods. The analytical pipeline is essential because network labels and estimates differ across approaches.
A proper audit should inspect dose, route of administration, scan timing relative to dosing, subjective rating instruments, motion summaries, physiological monitoring, exclusion criteria, nuisance regressors, global-signal treatment, and multiple-comparison corrections.
The analysis should also distinguish within-network integrity from between-network connectivity. Those metrics can support related but nonidentical claims about network disintegration or integration.
Interpretive disputes and alternatives
A principal dispute concerns whether observed BOLD-correlation changes reflect neural reorganization, altered neurovascular coupling, respiration and cardiovascular effects, vigilance changes, or a mixture of these influences. Acute serotonergic and stimulant-like drugs can affect several of these pathways.
Head motion is a major concern in resting-state fMRI, particularly when participants are intoxicated or physically uncomfortable. Even standard motion correction may not eliminate distance-dependent or network-specific artifacts.
The phrase “increased connectivity” can obscure heterogeneous effects and depends on the chosen baseline and preprocessing. Global-signal regression can especially affect anti-correlations and should be reported when interpreting reduced network opposition.
Small samples, numerous possible network-pair tests, and selective emphasis on visually compelling contrasts can inflate uncertainty. The study is valuable as an early mechanistic lead but should not be treated as a decisive stand-alone test of a general brain theory.
Transmission, reception, and commercial context
Academic discussion of this work contributed to a wider vocabulary of brain-network disintegration, integration, entropy, flexibility, and relaxed priors. These labels are theoretical interpretations layered over fMRI measurements rather than direct readouts of psychological constructs.
Popular accounts often translate these findings into claims that psychedelics connect the whole brain or permanently rewire it. Such statements are materially broader than an acute resting-state connectivity result.
Growing interest in psychedelic-assisted therapy and commercial drug development has increased incentives to communicate simple biomarkers of treatment action. This context can amplify a preliminary mechanistic finding without resolving whether it predicts clinical benefit.
The paper has no evidential bearing on paranormal cognition merely because it concerns unusual subjective states or altered consciousness.
Cross-case connections
This case connects to other pharmacological-fMRI studies that compare a classic psychedelic with placebo, ketanserin, LSD, ayahuasca, cannabis, ketamine, or an empathogen. The most useful comparison variables are dose, route, scan timing, participant overlap, network atlas, preprocessing, and subjective measures.
It also connects to methodological cases involving global signal, motion, physiological noise, and the distinction between static versus dynamic functional connectivity. These are recurrent sources of disagreement across consciousness neuroimaging.
A further connection is the gap between acute neural-state markers and longer-term therapeutic narratives. Cross-case analysis should code whether a study measured immediate subjective effects, clinical symptoms, follow-up outcomes, or only imaging correlates.
Limits of the recalled record
This dossier is an AI-recalled synthesis and not a verified reading of the article. Exact sample sizes, doses, condition order, scan parameters, network names, effect sizes, and statistical outcomes should not be relied upon without checking the primary paper.
The apparent 2015 date in one lead may reflect a citation error, a related publication, indexing timing, or conflation with another Imperial paper. The specific title is more strongly associated in memory with 2014.
No extraordinary inference follows from the work. Functional connectivity does not test telepathy, nonlocal consciousness, psi perception, or survival-related claims.
Chronology
Imperial psychedelic-imaging program develops
Controlled psilocybin neuroimaging studies at Imperial College London begin reporting changes in default-mode and large-scale-network measures.
approximateBetween-network comparison is published or circulated
Roseman and colleagues are recalled as reporting a resting-state fMRI comparison of psilocybin and MDMA effects on between-network functional connectivity.
reportedRelated-paper and dataset-overlap question emerges
Closely related Imperial papers may have used overlapping early datasets, making the precise publication date and sample independence important to establish.
disputedLater network-segregation literature expands
Newer psychedelic imaging studies revisit network integrity and segregation with different samples and analytic methods.
documentedPeople and roles
Leor Roseman
Recalled lead author.Associated in memory with the 2014 article; author order and affiliation should be verified.
Robin L. Carhart-Harris
Recalled collaborator and Imperial psychedelic-neuroimaging researcher.Associated with related theoretical and imaging work on psilocybin, but exact contribution to this paper should be checked.
David J. Nutt
Recalled collaborator and senior figure in the Imperial research program.Likely linked to the study’s broader pharmacology and clinical-research context; verify authorship.
Amanda Feilding
Recalled collaborator or associated funder/advocate in the research network.Her exact institutional and author role for this paper requires verification.
Robert Leech
Recalled collaborator with neuroimaging expertise.Likely associated with connectivity analysis; verify inclusion and role.
Imperial College London
Research institution and reported study location.The recalled institutional home of the research program in London, United Kingdom.
Connections to explore
Reduced network segregation during altered states
The case can be compared with psychedelic, anesthetic, psychosis-spectrum, meditation, sleep, and delirium imaging studies that ask whether canonical networks become less modular or more interdependent.
Suggested search: psilocybin reduced network segregation resting state fMRI canonical networksActive psychoactive comparator
MDMA provides a contrast with a different pharmacology and phenomenology, but it also introduces its own arousal, autonomic, and expectancy effects.
Suggested search: MDMA psilocybin active comparator resting state functional connectivityWithin-network versus between-network metrics
Studies can appear contradictory when one reports lower integrity within networks while another reports stronger coupling across networks, although both may describe reduced segregation.
Suggested search: psychedelic fMRI within network integrity between network connectivity distinctionResting-state fMRI confounds
Motion, respiratory variation, vascular effects, and global-signal handling are cross-cutting methodological variables in drug-state connectivity research.
Suggested search: pharmacological fMRI resting state global signal motion physiological confoundsOverlapping cohorts and pseudo-replication
Early specialist psychedelic-imaging programs often produced multiple papers from limited samples, requiring dataset provenance before counting findings as replications.
Suggested search: Imperial College early psilocybin fMRI dataset overlap Roseman Carhart-HarrisUnretrieved reference leads
The effects of psilocybin and MDMA on between-network resting state functional connectivity in healthy volunteers
Leor Roseman and collaborators. · Primary research article.
This is the central recalled paper and should settle the exact design, samples, doses, network contrasts, and statistics.
Suggested search: Roseman effects psilocybin MDMA between-network resting state functional connectivity healthy volunteersThe entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs
Robin L. Carhart-Harris and collaborators. · Theoretical review or article.
This is a likely source for the broader interpretive framework often attached to early Imperial psychedelic connectivity findings.
Suggested search: Carhart-Harris entropic brain theory conscious states neuroimaging psychedelic drugsNeural correlates of the psychedelic state as determined by fMRI studies with psilocybin
Robin L. Carhart-Harris and collaborators. · Primary research article.
This earlier Imperial psilocybin fMRI paper is useful for determining conceptual ancestry and possible cohort or dataset relationships.
Suggested search: Carhart-Harris neural correlates psychedelic state fMRI psilocybinPsilocybin-induced changes in brain network integrity and segregation
Joshua Siegel and collaborators. · Later primary research lead.
This is a nonduplicate later comparison point for modern evidence on psilocybin, network integrity, and segregation.
Suggested search: Siegel psilocybin brain network integrity segregation 2024 fMRI